Laura Deming
Laura Deming is a venture capitalist focused on life extension and aging research. She is the founder and partner of The Longevity Fund, an early-stage venture capital firm backing companies that target the aging process to treat disease, and co-founder of age1, a next-generation longevity fund launched in 2023. She began working in aging biology at age 12 in Cynthia Kenyon's lab at UCSF, entered MIT at 14, and left to accept a Thiel Fellowship at 17 to start her venture firm. She is best known for being one of the earliest investors dedicated exclusively to longevity-focused biotech companies.
“On your blog, you recommend Laura Deming's The Rage of Research... It captures that spirit that just like, I have to.”
Source→“She tweeted, hey, we've got COVID testing capacity, does anybody want some, and the deputy mayor of LA slid into her DMs and was like, yes please, we would like to talk about that.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.